Guardant Health Valuation
Is GH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GH * (MX$301) is trading below our estimate of fair value (MX$450.44)
Significantly Below Fair Value: GH * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GH *?
Other financial metrics that can be useful for relative valuation.
What is GH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.11b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.1x |
Enterprise Value/EBITDA | -5.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GH *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1x | ||
MEDICA B Médica Sur. de | 1.1x | 5.2% | Mex$4.4b |
PRVA Privia Health Group | 1.3x | 9.9% | US$2.2b |
AMN AMN Healthcare Services | 0.6x | -1.9% | US$2.2b |
MCOV B Medicover | 1.2x | 14.5% | kr25.7b |
GH * Guardant Health | 3.9x | 17.0% | Mex$2.1b |
Price-To-Sales vs Peers: GH * is expensive based on its Price-To-Sales Ratio (3.9x) compared to the peer average (1x).
Price to Earnings Ratio vs Industry
How does GH *'s PE Ratio compare vs other companies in the South American Healthcare Industry?
Price-To-Sales vs Industry: GH * is expensive based on its Price-To-Sales Ratio (3.9x) compared to the South American Healthcare industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is GH *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.9x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GH *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$670.75 0% | 20.8% | Mex$850.96 | Mex$459.52 | n/a | 17 |
Apr ’25 | Mex$293.83 | Mex$697.21 +137.3% | 19.9% | Mex$901.47 | Mex$450.73 | n/a | 17 |
Mar ’25 | Mex$360.00 | Mex$709.41 +97.1% | 19.4% | Mex$923.08 | Mex$461.54 | n/a | 18 |
Feb ’25 | n/a | Mex$796.06 0% | 18.5% | Mex$1,033.35 | Mex$465.01 | n/a | 18 |
Jan ’25 | n/a | Mex$806.05 0% | 18.9% | Mex$1,092.44 | Mex$460.87 | n/a | 18 |
Dec ’24 | n/a | Mex$848.36 0% | 18.8% | Mex$1,125.93 | Mex$475.00 | n/a | 18 |
Nov ’24 | n/a | Mex$925.71 0% | 18.1% | Mex$1,349.41 | Mex$620.00 | n/a | 17 |
Oct ’24 | Mex$478.43 | Mex$937.23 +95.9% | 17.6% | Mex$1,308.58 | Mex$601.24 | n/a | 17 |
Sep ’24 | n/a | Mex$922.26 0% | 15.0% | Mex$1,265.22 | Mex$683.90 | n/a | 17 |
Aug ’24 | Mex$662.50 | Mex$898.15 +35.6% | 20.2% | Mex$1,256.82 | Mex$509.52 | n/a | 17 |
Jul ’24 | n/a | Mex$928.94 0% | 20.3% | Mex$1,304.24 | Mex$528.75 | n/a | 17 |
Jun ’24 | n/a | Mex$928.94 0% | 20.3% | Mex$1,304.24 | Mex$528.75 | n/a | 17 |
May ’24 | Mex$444.00 | Mex$1,003.91 +126.1% | 25.1% | Mex$1,628.47 | Mex$610.67 | n/a | 16 |
Apr ’24 | n/a | Mex$1,003.91 0% | 25.1% | Mex$1,628.47 | Mex$610.67 | Mex$293.83 | 16 |
Mar ’24 | n/a | Mex$1,047.06 0% | 20.1% | Mex$1,620.07 | Mex$662.76 | Mex$360.00 | 16 |
Feb ’24 | Mex$591.33 | Mex$1,216.16 +105.7% | 19.0% | Mex$1,643.34 | Mex$672.27 | n/a | 16 |
Jan ’24 | n/a | Mex$1,357.64 0% | 16.1% | Mex$1,760.63 | Mex$978.13 | n/a | 15 |
Dec ’23 | n/a | Mex$1,529.80 0% | 14.2% | Mex$1,921.96 | Mex$970.69 | n/a | 15 |
Nov ’23 | Mex$972.48 | Mex$1,831.32 +88.3% | 21.4% | Mex$2,563.59 | Mex$986.00 | n/a | 15 |
Oct ’23 | Mex$1,100.84 | Mex$1,906.03 +73.1% | 21.8% | Mex$2,585.23 | Mex$1,292.62 | Mex$478.43 | 13 |
Sep ’23 | Mex$1,006.02 | Mex$1,906.03 +89.5% | 21.8% | Mex$2,585.23 | Mex$1,292.62 | n/a | 13 |
Aug ’23 | Mex$1,051.09 | Mex$2,028.90 +93.0% | 19.5% | Mex$2,648.61 | Mex$1,324.30 | Mex$662.50 | 12 |
Jul ’23 | Mex$812.19 | Mex$2,184.48 +169.0% | 23.4% | Mex$3,225.40 | Mex$1,270.61 | n/a | 12 |
Jun ’23 | Mex$842.65 | Mex$2,335.69 +177.2% | 19.9% | Mex$3,322.32 | Mex$1,711.50 | n/a | 11 |
May ’23 | n/a | Mex$2,542.88 0% | 16.5% | Mex$3,366.40 | Mex$1,856.62 | Mex$444.00 | 11 |
Apr ’23 | n/a | Mex$2,578.15 0% | 16.8% | Mex$3,400.44 | Mex$1,875.39 | n/a | 10 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.